20,426 Shares in Johnson & Johnson (JNJ) Purchased by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,426 shares of the company’s stock, valued at approximately $2,656,000.

Other large investors also recently added to or reduced their stakes in the company. Harding Loevner LP bought a new stake in Johnson & Johnson during the 2nd quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth $124,000. Shine Investment Advisory Services Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth $177,000. Finally, Lenox Wealth Management Inc. raised its stake in shares of Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after buying an additional 24 shares in the last quarter. Institutional investors and hedge funds own 67.35% of the company’s stock.

In other news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.19% of the company’s stock.

Shares of Johnson & Johnson (JNJ) opened at $134.35 on Wednesday. The stock has a market capitalization of $360,450.00, a price-to-earnings ratio of 24.74, a PEG ratio of 2.19 and a beta of 0.77. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a 52-week low of $120.95 and a 52-week high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. The company had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. Johnson & Johnson’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.58 earnings per share. research analysts anticipate that Johnson & Johnson will post 8.11 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were issued a dividend of $0.84 per share. The ex-dividend date was Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.50%. Johnson & Johnson’s dividend payout ratio is 61.88%.

A number of research firms have recently commented on JNJ. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective on the stock in a research note on Thursday, January 11th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research note on Monday, January 22nd. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Finally, Stifel Nicolaus boosted their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $146.26.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/03/14/20426-shares-in-johnson-johnson-jnj-purchased-by-valeo-financial-advisors-llc.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply